Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.50 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19630492 | 1.00 | PREP (0.57) | PREPACE2KMT2ACTRB1KLK7 | |
| SCHEMBL21074208 | 1.00 | PREP (0.57) | PREPACE2KMT2ACTRB1KLK7 | |
| SCHEMBL19615561 | 1.00 | PREP (0.57) | PREPACE2KMT2ACTRB1KLK7 | |
| SCHEMBL19630544 | 1.00 | PREP (0.57) | PREPACE2KMT2ACTRB1KLK7 | |
| SCHEMBL9872401 | 0.87 | PREP (0.61) | PREPACE2KMT2ACTRB1KLK7 | |
| SCHEMBL9872394 | 0.87 | PREP (0.61) | PREPACE2KMT2ACTRB1KLK7 | |
| SCHEMBL19258607 | 0.86 | PREP (0.63) | PREPACE2KMT2ACTRB1KLK7 | |
| SCHEMBL3690397 | 0.86 | PREP (0.57) | PREPACE2KMT2ACTRB1KLK7 | |
| SCHEMBL10774349 | 0.85 | PREP (0.59) | PREPACE2CTRB1NPSR1TSHR | |
| SCHEMBL9872311 | 0.85 | PREP (0.59) | PREPACE2CTRB1NPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458584-B1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | CONSEJO SUPERIOR INVESTIGACION (ES) | 2021-07-07 | — | — | EP | disclosed |
| US-10683493-B2 | Fusion proteins comprising an aldolase enzyme joined to a maltose binding protein | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2020-06-16 | — | — | US | disclosed |
| US-20190194638-A1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | TECHNICAL UNIVERSITY OF DARMSTADT (DE) | 2019-06-27 | — | — | US | disclosed |
| EP-3458584-A1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | Consejo Superior De Investigaciones Científicas (ES) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198717-A1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194638-A1 | FUSION PROTEINS COMPRISING AN ALDOLASE ENZYME JOINED TO A MALTOSE BINDING PROTEIN | ALDOA, TALDO1, DERA | PREP 488/4885ACE2 593/4885KMT2A 1688/4885 |
| US-10683493-B2 | Fusion proteins comprising an aldolase enzyme joined to a maltose binding protein | ALDOA, TALDO1, DERA | PREP 488/4885ACE2 593/4885KMT2A 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.